UroGen Pharma(US:URGN) ZACKS·2025-05-12 14:15Company Performance - Urogen Pharma reported a quarterly loss of $0.92 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.83, and an improvement from a loss of $0.97 per share a year ago, indicating a surprise of -10.84% [1] - The company posted revenues of $20.25 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 3.67%, but showing an increase from $18.78 million in the same quarter last year [2] - Over the last four quarters, Urogen Pharma has surpassed consensus EPS estimates only once and has topped consensus revenue estimates just once [2] Stock Outlook - Urogen Pharma shares have declined approximately 2.5% since the beginning of the year, while the S&P 500 has seen a decline of 3.8%, indicating relative outperformance [3] - The current consensus EPS estimate for the upcoming quarter is -$0.85 on revenues of $24.45 million, and for the current fiscal year, it is -$3 on revenues of $120.83 million [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Urogen Pharma belongs, is currently ranked in the top 34% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]